BLTE
Belite Bio, Inc
A clinical-stage biopharmaceutical company developing an oral pill, tinlarebant, meant to slow vision loss in inherited retinal diseases like Stargardt disease and geographic atrophy. Founded by Dr. Tom Lin, it grew out of his earlier drug company Lin BioScience and went public on the Nasdaq in 2022, with headquarters in San Diego. Its name is often read as a nod to its mission of helping people "be light" by protecting their sight.
ADRUnderlying: BLTECUSIP: 07782B104HealthcareUS1 holder
Sponsored American Depositary Shares
Total Value
$61.03M
Total Shares
396.3K
Net Share Change
+396.3K
Activity
1 buying
Investor
Value
Shares
Weight
Change
